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I. INTRODUCTION 
The American Society for Blood and Marrow Trans- 
plantation (ASBMT) in 1999 began an initiative to sponsor 
evidence-based reviews of the scientific literature for the use 
of blood and marrow transplantation i  the therapy of 
selected iseases. A steering committee was convened to 
oversee the project and to appoint an independent panel of 
experts to conduct each review. 
The following is the first review to result from the ini- 
tiative. Its goals were to: 
1. assemble and critically evaluate all of the evidence 
regarding the role of cytotoxic therapy with 
hematopoietic stem cell transplantation (SCT) in 
the therapy of diffuse large cell B-cell non-Hodgkin's 
lymphoma (DLCL); 
2. make treatment recommendations based on the 
available vidence; and 
3. identify needed areas of research. 
The published literature was graded on the quality of 
design (Table 1) and the strength of the evidence (Table 2) 
in a systematic manner. Treatment recommendations were 
subsequently graded based on the quality and strength of 
the evidence (Table 3). The treatment recommendations of 
the expert panel based on these criteria for evaluating the 
evidence are detailed in Section X (Tables 13 and 14). 
At least one prospective multicenter (international) ran- 
domized clinical trial is represented in each of the major 
sections of this review, including: 
9 comparison of SCT to standard chemotherapy in 
first or subsequent relapse; 
9 first complete response/remission (CR) after full- 
course standard induction; 
9 first partial response/remission (PR) after abbrevi- 
ated standard induction; and 
9 up-front high-dose sequential therapy. 
Other supporting evidence is described, as well as stud- 
ies that investigate special subgroups (eg, age, imnmnophe- 
notype) and specific SCT techniques (eg, tandem/double 
transplantations, stem cell mobilization, autologous versus 
allogeneic SCT). 
II. LITERATURE SEARCH METHODOLOGY 
MEDLINE, the Web site of the National Library of 
Medicine, National Institutes of Health, was searched using 
the MeSH term "Non-Hodgkin's Lymphoma" limited to 
"Drug Therapy" or "Therapy." Search criteria were limited 
to English language, human trials, and publication dates 
between January 1980 and December 2000. In addition, a 
hand search was conducted of abstracts published by the 
American Society of Hematology in Blood, the American 
Society of Clinical Oncology in ffournal of Clinical Oncology, 
and the European Group for Blood and Marrow Transplan- 
tation in Bone Marro-w Transplantation for the meeting years 
1997-2000; and for abstracts published in Annals of Oncology 
by the International Conference on Malignant Lymphoma 
for the 1999 meeting year. 
DLCL was defined as the Revised European-American 
Classification of Lymphoid Neoplasms (REAL) [1] or 
World Health Organization (WHO) [2] classification of 
diffuse large B-cell lymphoma; or International Working 
Formulation (IWF) [3] subtypes F (diffuse mixed large and 
small cells), G (diffuse large cell) and H (diffnse large cell 
immunoblastic); or Kiel Classification [4,5] centroblastic, 
centroblastic-centrocytic (diffuse), centrocytic (large) and 
immunoblastic B-cell; or Rappaport classification [6] diffuse 
histiocytic B-cell lymphoma. 
Published articles and abstracts tudying SCT were 
included only if DLCL patients made up a minimum of 
70% of the study population, unless results were stratified 
by histology subtype. The proportion of the study popula- 
tion with anaplastic large cell lymphoma is presented in the 
grading summary at the end of each major section but was 
not considered in calculating the 70% minimum required 
for inclusion. 
More than 250 abstracts and manuscripts hat met the 
initial search criteria were ultimately excluded because they: 
9 did not study cytotoxic therapy with SCT; 
9 studied therapy for relapse after SCT (studies of 
second transplantations were not excluded); 
9 did not assess overall survival (OS), disease-free 
survival (DFS) or event-free survival (EFS) (with 
the exception of studies of stem cell mobilization 
techniques); 
9 did not state the histologic subtypes (by IWF, Kiel, 
Rappaport, REAL or YVHO classifications); 
9 stated the histologic subtypes but included fewer 
than 70% DLCL patients or did not stratify the 
results by subtype; 
9 studied H1V-associated lymphomas; 
9 conducted a Phase I study (dose-escalation r
dose-finding study); 
9 were reviews of the literature, editorials, case 
reports, or letters to the editor; and/or 
9 were abstracts subsequently published as manuscripts. 
A list of all excluded manuscripts and abstracts i avail- 
able at the ASBMT Web site www.asbmt.org. 
III. QUALITATIVE AND QUANTITATIVE GRADING OF 
EVIDENCE 
The hierarchy of evidence, including" a grading scheme 
for the quality of the evidence, strength of the evidence, and 
strength of each recommendation, has been established and 
published as an editorial policy statement in Biology of Blood 
and Marrow Transplantation [7]. Tables 1 to 3 are reprinted 
from the policy statement and define the criteria used to 
grade the studies included in the review and the treatment 
recommendations. Study design, including sample size, 
patient selection criteria, duration of follow-up, and treat- 
ment plan, also were considered in evaluating the studies. 
IV. FIRST OR SUBSEQUENT RELAPSE 
There has been only 1 randomized multicenter trial 
(level 1 evidence; Table 1) comparing autologous bone mar- 
row transplantation (BMT) with standard salvage chemo- 
therapy in relapsed DLCL patients. This trial is described in 
detail in the chemotherapy-sensitive relapse section below, 
along with supporting evidence from retrospective cohort 
and prospective phase II studies (level 2 evidence; Table 1). 
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Figure I. Kaplan-Meier curves for event-free survival of patients in 
the transplantation a d the conventional treatment groups. The data 
are based on an intention-to-treat nalysis. Tick marks represent cen- 
sored data. Reprinted with permission from Philip T, Guglielmi C, 
ttagenbeek A, et al. Autologous bone marrow transplantation as com- 
pared with salvage chemotherapy in relapses of chemotherapy-sensitive 
non-Hodgkin's lymphoma. NEnglff Med. 1995;333:1540-1545. Copy- 
right 9 1995 Massachusetts Medical Society. All rights reserved. 
There  haye been no randomized trials that include 
DLCL  patients with chemotherapy-resistant,  pr imary 
refractory, or untested relapsed disease. The results of sev- 
eral retrospective cohorts and prospective phase II efficacy 
studies that compare the impact of chemotherapy sensitivity 
to the impact of chemotherapy resistance on BMT outcome 
are summarized in the following appropriate sections. 
A. Chemotherapy-Sensit ive Disease 
The PARMA trial compared autologous BMT with sal- 
vage chemotherapy  in chemotherapy-sens i t i ve  non-  
Hodgkin's lymphoma (NHL)  patients [8-10]. A total of 
215 intermediate- or high-grade NHL  patients in first (n = 
188) or second (n = 27) relapse were enrolled. To be eligible, 
Table I. Grading the Quality of the Evidence* 
I Evidence obtained from at least one properly randomized con- 
trolled trial 
2-I Evidence obtained from well-designated, controlled trials with- 
out randomization 
2-2 Evidence obtained from well-designated, cohort or case- 
controlled analytic studies, preferably from more than one cen- 
ter or research group 
2-3 Evidence obtained from multiple t imed series with or without 
the intervention, or from dramatic results in uncontrolled 
experiments 
3 Opinions of respected authorities based on clinical experience, 
descriptive studies, or reports of expert committees 
4 Evidence inadequate owing to problems of methodology, e.g., 
sample size, length or comprehensiveness of follow-up, or con- 
flict in evidence 
*Reprinted with permission from Shipp MA, Abeloff MD, Antman 
KH, et al. International Consensus Conference on High-Dose Ther- 
apy with Hematopoietic Stem Cell Transplantation i  Aggressive 
Non-Hodgkin's Lymphomas: report of the jury. ff Cliu Oncol. 
1999;17:423-429. 
patients must have received a doxorubicin-containing duc- 
t ion regimen and maintained a CR for a min imum of 
4 weeks. M1 patients received 2 salvage courses of dexametha- 
sone, cisplatin, and cytarabine (DHAP). Bone marrow (BM) 
was harvested after the first course of DHAP. 
One hundred nine patients with CR or PR to DHAP 
were randomized to receive 4 additional DHAP courses and 
involved field radiotherapy (IFRT) to bulky disease sites (n = 
54) or autologous BMT with carmustine, etoposide, cytara- 
bine and cyclophosphamide (BEAC) conditioning and IFRT 
to bulky disease sites or extranodal lesions (n = 55). Prog- 
nostic factors were similar in the 2 groups. 
With a median follow-up of 63 months, the overall 
response rate was 84% after BMT versus 44% after salvage 
chemotherapy. The 5-year EFS was 46% in the BMT group 
versus 12% in the chemotherapy group (P = .001). OS at 
5 years was 53% in the BMT group versus 32% in the con- 
ventional treatment group (P = .038 [Figure 1]). 
A subsequent retrospective analysis of the PARMA trial 
[11] investigated the prognostic value of the International 
Prognostic Index (IPI) at relapse [12]. (See Appendix B for 
definitions of the IPI risk categories.) At a 79-month median 
follow-up, the 5-year OS was 46%, 25%, 25% and 11% for 
patients with an IPl of 0, 1, 2, and 3, respectively (P < .001). 
As shown in Figure 2, IPI  at relapse was significantly corre- 
lated with OS in the salvage chemotherapy group (5-year 
OS 48%, 21%, 33%, 0% for IPI 0, 1, 2, 3, respectively [P = 
,006]) but not in the BMT group (5-year OS 51%, 47%, 
50%, 50% for IPI 0, 1, 2, 3, respectively [P = .90]). OS was 
Table 2. Gradif N the Strength of the Evideme * 
I Experimental therapy significantly better (P < 0.05) 
2 Trend in favor of experimental therapy (P > 0.05) 
3 No apparent statistical effect 
4 Trend favoring control group (P > 0.05) 
5 Control group significantly better (P < 0.05) 
*Reprinted with permission from Chalmers TC, Berrier J, Sacks 
HS, Levin H, Rein'nan D, Nagalingam R. Meta-analysis ofclinical tri- 
als as a scientific discipline. II: Replicate variability and comparison of 
studies that agree and disagree. Star Med. 1987;6:733-744. 
Table 3. Grading the Strength of the Treatment Recommendation* 
I Effective treatment 
2 Marginally effective treatment 
3 Not an effective treatment (no statistical or clinical difference 
between therapies) 
4 Inadequately evaluated treatment and recommended for 
comparative study 
5 Inadequately evaluated treatment but not recommended for 
comparative study 
*Based on Tables 1 and 2. Reprinted with permission from Jones R, 
Horowitz M, Wall D, et al. ASBMT policy statement regarding the 
methodology ofevidence-based r views in evaluating the role of blood 
and marrow transplantation in the treatment of selected isease. Bid 
Blood Marrow Transplant. 2000;6:524-525. 
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F igure  2. Overall survivml of 106 randomized patients according to the International Prognostic Index (IPI) at relapse. Survival is calculated from 
the first day of the first course of dexamethasone, cisplatin, and cytarabine (DHAP). A, Survival of patients in the DHAP arm according to the IPI. 
B, Survival of patients in the ABMT arm according to the IPI. C, Patients with IPI = 0, DHAP versus ABMT arm. D, Patients with IPI = 1-3, 
DHAP versus ABMT arm. Reprinted with permission from Nay JY, Gomez F, Sebban C, et al. on behalf of the PARMA Group. The International 
Prognostic Index correlates to survival in patients with aggressive lymphoma inrelapse: analysis of the PARMA trial. Blood. 1998;92(10):3562-3568. 
Copyright 01998 American Society of Hematology. 
significantly better in the BMT group compared to the sal- 
vage chemotherapy group in patients with an IPI >0, but not 
in the patients with an IPI ; 0. 
The PARMA trial's results were assessed by Kanjeekal 
et al. in a population of patients who did not meet the 
trial's strict eligibility criteria [13]. (This study did not give 
information on histology; however, patient selection was 
based on factors comparable to those in the PARMA trial, in 
which 73% of patients were diagnosed with DLCL.)  Two 
reviewers blinded to treatment and outcome retrospectively 
reviewed 60 patients, 27 of whom received SCT. Among 
those who received SCT, 19% (5/27) were "PARMA eligi- 
ble." Eighty-one percent (22/27) did not meet the eligibility 
criteria of the PARMA trial due to primary refractory dis- 
ease (26%), failure to achieve a PR (20%), salvage therapy 
other than DHAP (48%), or age greater than 60 years 
(30%). There was no detectable difference in the 2-year 
progression-flee survival (PFS) (P = .38) or OS (P = .41) 
between PARMA eligible and ineligible patients. 
Among the 27 SCT patients, 17 (63%) were judged 
appropriate for SCT using the PARMA eligibility criteria; 
10 (37%) were judged inappropriate. There was no signifi- 
cant difference in the 2-year PFS (32% versus 15%; P = .3) 
or OS (48% versus 30%; P = .14) between the groups 
judged appropriate and inappropriate for SCT using the 
PARMA eligibility criteria. 
Prince et al. sought to retrospectively identify major 
prognostic factors predicting outcome in 81 patients with 
chemotherapy-sensitive relapsed disease (at minimum, a 
PR to salvage therapy after first relapse) who underwent 
transplantations with melphalan and etoposide with or 
without total body irradiation (TBI) [14]. Their multivari- 
ate model assessed the following variables: age, histology, 
stage at diagnosis, immunophenotype, extranodal disease 
at diagnosis, prior BM involvement, bulky disease at diag- 
nosis, duration of prior CR, number of cycles of conven- 
t iona l -dose salvage chemotherapy ,  tumor  burden at 
relapse, relapse in a previous radiation field, and remission 
status immediately prior to BMT. Remission status at 
BMT was the only significant variable that predicted OS 
and PFS (P = .0001). Patients who received transplants in 
CR had a significantly better 4-year OS and PFS than 
those who received transplants in PR (OS 72 % versus 
26%; PFS 61% versus 25%). 
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Verdonck et al. used an alternative salvage regimen of 
prednisone, methotrexate, doxorubicin, cyclophosphamide, 
etoposide, mechlorethamine, vincristine, and procarbazine 
(ProMACE-MOPP) before BMT in 31 patients with pri- 
mary refractory disease or relapsed from CR after induction 
with cyclophosphamide, oxorubicin, vincristine, and pred- 
nisone (CHOP) [i5]. Of 28 ProMACE-MOPP responders, 
17 (61%) patients underwent autologous BMT with 
cyclophosphamide and TBI (CT) conditioning. Of the 31 
ProMACE-MOPP patients, there was an overall response 
(CR/PR) rate of 90% with a 3-year DFS of 25%. 
Stamatoullas et al. studied the feasibility of peripheral 
blood SCT (PBSCT) for patients over the age of 60 [16]. Of 
the 13 enrolled in the study, 9 patients, with a median age of 
62 (range, 61-70), underwent PBSCT with carmustine, 
etoposide, cytarabine, and melphalan (BEAM) conditioning 
regimen; at transplantation, 8 had chemotherapy-sensitive 
disease (first or second CR) and 1 had primary refractory 
disease. Of the 8 with chemotherapy-sensitive dis ase at 
transplantation, there was 1 early toxic death, 4 patients 
relapsed and died during the first 3 months post-PBSCT, 
and 3 are alive in CR 8 to 14 months post-PBSCT. Before 
PBSCT, all patients had an Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) <2. At discharge, 
7 of the 8 surviving patients had an ECOG PS of 3, and 
only 2 recovered to a PS of 0 at 2 and 5 months post- 
PBSCT. The remaining 5relapsed before PS recovery. 
Gugliehni et al. retrospectively analyzed 247 DLCL 
patients who underwent transplantation in first chemo- 
therapy-sensitive relapse to determine which factors were 
predictive for OS and EFS [17]. Sixty-two percent of the 
patients had a low- or low-intermediate-risk IPI score at 
time of diagnosis. First relapse occurred amedian of 258 days 
after first CR, and SCT was performed a median of 153 days 
after first relapse. OS was 52% and EFS was 45% at 5 years. 
Three factors had independent prognostic value by multi- 
variate analysis: BM involvement at first relapse, PS at first 
relapse, and duration of first CR. The effects of the 3 factors 
were cumulative: 30% had no adverse factors with an OS of 
76% and EFS of 69%; 51% had 1 adverse factor with an OS 
of 55% and EFS of 48%; 19% had 2 or 3 adverse factors 
with an OS of 31% and EFS of 21%. 
THE EVIDENCE FOR TRANSPLANTATION IN CHEHOTHERAPY- 
SENSITIVE RELAPSED DISEASE 
There are no prospective studies comparing condition- 
ing regimens, stem cell mobilization techniques, tem cell 
source, or donor type for chemotherapy-sensitive relapsed 
disease. The only evidence that has been systematically eval- 
uated is the PARMA trial [8-10] using BEAC conditioning 
and autologous BM as a stem cell source. Although there is 
no evidence specific to DLCL patients, the standard of care 
has changed from using autologous BMT to autologous 
PBSCT. This change is based on registry data, retrospective 
comparisons, and clinical experience, including all NHL 
subtypes. (PBSCTs have not been rigorously compared to 
BMTs in prospective clinical trials in DLCL patients; how- 
ever, PBSCTs appear to result in improved outcomes in a 
variety of diseases.) 
There are no data to establish whether allogeneic 
donors, immunotherapy, or conditioning and stem cell 
mobilization regimens different han those used in the 
PARMA trial may improve outcomes in chemotherapy- 
sensitive relapsed DLCL patients. These are possible areas 
for future research. 
The following 2 sections ummarize f asibility studies of 
purging and immunotherapy in chemotherapy-sensitive 
relapsed DLCL patients. 
Purging or Positive Selection. Weisdorf et al. performed a 
prospective nonrandomized trial using in vitro-purged 
autologous BMT in 70 patients with low-grade (n = 15), 
intermediate-grade (n = 25) or high-grade (n = 30) NHL 
(results stratified by NHL grade) [18]. Marrow obtained 
from 42 patients with B-cell immunophenotype was 
purged in vitro with monoclonal antibodies (anti-CD9, 
-CD10, and -CD24) plus complement. Twelve patients 
with T-cell immunophenotype received marrow purged 
with monoclonal antibodies conjugated with immunotox- 
ins (ant i -CD5- and anti-CDT-ricin conjugates) and 
4-hydroperoxycyclophosphamide; 16 patients received 
unpurged BM. Seventy percent of patients had either 
chemotherapy-sensitive or untested relapsed isease or a 
PR to induction therapy at time of transplantation; the 
remainder had primary refractory or chemotherapy-resis- 
tant relapsed isease. 
The data on purging technique and patient characteris- 
tics summarized above are for all 70 NHL patients. Among 
intermediate-grade (92% IYVF F/G) NHL patients (n = 25), 
there was no difference in hematologic recovery between 
purged and unpurged BMTs. At day 28 post-BMT, 69% 
were alive in CR. The 2-year OS and EFS were 31% and 
24%, respectively. Purging technique (T versus B versus no 
purging) and immunophenotype (T versus B) had no associ- 
ation with relapse or survival post-BMT. 
Use of lmmu~otherapy. Weinberger et al. performed a
feasibility study using anti-CD20 antibody (rituximab) 
treatment before PBSC collection and after PBSCT in 5 
patients either with chemotherapy-sensitive relapsed is- 
ease (n = 3) or with disease refractory to induction but sen- 
sitive to salvage therapy (n = 2) [19]. Rituximab was admin- 
istered twice over 2 weeks prior to hematopoietic growth 
factor-mobilized PBSC collection, followed by PBSCT. 
Cyclophosphamide, carmustine, and etoposide (CBV) or 
etoposide and cyclophosphamide plus TBI (VCT) were 
used as conditioning, After hematologic recovery and 
before day 42 post-PBSCT, 2 additional weekly doses of 
rituximab were administered. The addition of rituximab to 
the pre- and posttransplantation regimen was well tolerated 
without evidence of delayed engraftment. All 5 patients 
remained in remission 37 to 355 days post-PBSCT. 
Table 4 summarizes the evidence outlined above from 
the published literature studying SCT in chemotherapy- 
sensitive relapsed isease. 
B. Chemotherapy-Resistant Relapse and Primary 
Refractory Disease 
Two early studies demonstrated the feasibility of BMT 
as salvage therapy in poor-prognosis patients for chemo- 
therapy-resistant relapse or primary refractory disease 
[20,21]. Subsequent s udies have compared the efficacy of 
BMT in NHL  patients by remission status at time of 
BMT. All studies have shown that patients undergoing 
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Table 4. Grading Summary of the Evide'nce for SCT in Chemotherapy-Se~sitive Relapsed Disease* 
Strength of Evidence~ 
Quality of Median 
Reference Evidence t OS EFS DFS Fellow-up, mo 
No. of 
Patients ALCL  IWF F/G/H 
Philip et al. [8] I I I NA  63 109 0% 73% 
Blay et al. [ I  I] I I~ NA I~ 79 215 0% 73% 
Kanjeekal et al. [ 13] 2-2 3 NC 3 NS 27 w w 
Prince et al. [14] 2-1 NC NA NC 37 81 0% 80% 
Verdonck et al. [15] 2-1 NA NA NC 33 17 0% 71% 
Stamatoullas et al. [ 16] 2- I NC NC NC NS 13 0% 92% 
Guglielmi et al. [ 17] 2-2 NC NC NC 48 247 NS 100% 
Weisdorf et al. [ 18] 2- I NC NA NC 36 70 0% FIG 92% 
H 30% 
Weinberger et al [ 19] 2- I NA  NA NA NS 5 0% 100% 
*SeT indicates hematopoietic stem cell transplantation; OS, overall survival; EFS, event-free survival; DFS, disease-free survival; ALCL, 
anaplastic large cell lymphoma; IWF, International Working Formulation; F, diffuse mixed cell; G, diffuse large cell; H, diffuse large cell 
immunoblastic; NC, no comparison i study between HDT/SCT and standard chemo; NA, not applicable; NS, not stated. 
]-See Tables 1 and 2 for definitions. 
{For patients with an IPI >0. 
w not stated; however, study eligibility criteria same as that for Philip et al. [8]. 
BMT for chemotherapy-resistant relapsed and/or primary 
refractory disease have significantly decreased survival 
compared to patients who received transplants for chemo- 
therapy-sensitive disease [22-31]. Two studies showed the 
same effect in patients with primary mediastinal DLCL 
[32,33]. One study also demonstrated that DLCL patients 
with relapsed or refractory primary mediastinal disease had 
improved DFS and OS compared to DLCL patients with 
disease at other sites [33]. Although these studies are level 
2 evidence (Table I), the data are consistent across multi- 
ple centers. Tables 5 and 6 summarize the range of OS, 
or EFS and DFS, or PFS by chemotherapy sensitivity for 
these studies. 
Kewalramani et al. retrospectively analyzed outcomes 
for 85 primary refractory NHL  patients [34]. Forty patients 
had a PR after induction therapy (IPR) and 45 patients 
experienced induction failure (IF). Patients were given 
3 cycles of ifosfamide, carboplatin, etoposide/granulocyte 
colony-stimulating factor (ICE/G-CSF) to mobilize PBSCs 
that were collected after the third cycle. Conditioning regi- 
mens were CBV, BEAM, high-dose ICE, ifosfamide/etopo- 
side/TBI, or VeT,  depending on age, prior therapy, and 
active trials at time of SeT. 
Of 85 patients who underwent ICE/G-CSF chemo- 
therapy and mobilization, 43 (50.6 %) achieved a CR (n = 
14) or PR (n = 29). Five of these 43 patients had progres- 
sive disease before conditioning regimen and did not 
receive transplants. In addition, 4 patients who failed to 
respond to ICE underwent SeT. Among the 42 PBSCT 
patients, 4 died of progressive disease before day 100, 
none of transplantation-related causes. OS was 52.5% and 
EFS was 44.2%. In an intent-to-treat nalysis, the 3-year 
OS and EFS were 25% and 22%. The IPR group had a 
statistically significantly higher OS compared to the IF 
group (P = .015). There was no significant difference, 
however, in EFS between the groups (P = .081). For the 
subset of patients who underwent autologous SeT, there 
was no difference in the OS or EFS between the IPR and 
IF groups. 
THE EVIDENCE FOR TRANSPLANTAT ION IN CHEHOTHERAPY-  
RESISTANT/REFRACTORY DISEASE 
There are no prospective randomized trials comparing" 
stem cell source, donor type, conditioning, or mobilization 
regimens in chemotherapy-resistant relapsed or primary 
refractory DLCL patients. The following sections umma- 
rize the level-2 evidence concerning IFRT, stem cell 
sources, stem cell mobilization regimens, allogeneic BMTs, 
and imnmnotherapy in resistant/refractory patients. 
Role of I'nvolved Field Radiotherapy. Mundt et al. evaluated 
the role of IFRT on the rate and sites of relapse in DLCL 
patients [35]. Fifty-three adult patients with refractory (n = 
14) or relapsed (n = 39) disease underwent BMT or PBSCT 
with chemotherapy-only conditioning regimens. Seven (13 %) 
patients received IFRT before (n = 1) or after (n = 6) SCT. 
Among patients urviving beyond day 30 post-BMT, none of 
the 7 IFRT patients relapsed in prior sites of disease, com- 
pared to 16 of 39 (41%) patients without IFRT. Three of 7 
(43%) patients with IFRT and 12 of 39 (31%) patients with- 
out IFRT relapsed in new sites of disease. There were 141 
sites of disease before induction therapy. The most common 
site was nodal (79%), 12% of which were >5 cm. Patients 
who received IFRT had significantly improved 4-year local 
control overall compared to those who did not receive IFRT 
(100% versus 61.1%; P = .05), in sites failing to achieve CR to 
induction (100% versus 32%; P = .01) and in sites failing to 
achieve aCR to SCT (100% versus 29.4%; P = .01). 
Hematopoietic Stem Cell Sources. Vose et al. performed a
retrospective multivariate analysis of 158 relapsed or primary 
refractory DLCL patients in order to develop a prognostic 
model for autotransplantation patients [36]. Good prognosis 
was defined as no mass >10 cm and no more than 1 of the 
following adverse factors: 3 or more prior chemotherapy 
regimens, serum lactate dehydrogenase (LDH) level greater 
than normal, chemotherapy resistance. The poor-prognosis 
group included patients with a mass >10 cm or with 2 
adverse factors. 
In the poor-prognosis group, there was no difference in 
the 3-year EFS in patients who received autologous BM 
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Table 5. Comparison of Overall o~" Evem-Fvee Su*-oivM by Disease Status at T#ne of SCT* 
Overall or Event-Free Survival 
Number of 
Reference Patients 2 y 3 y 4 y 5 y 6y 
Kaplan-Meier Survival Percentages 
Resistant Chemo-sensitive Untested 
Relapse/Refractory Relapse Relapse 
Gribben et al. [27] 50 
Stiff et al. [24] 94 
Saez et al. [22] 45 
Wheeler et al, [26] 78 
Popat et al, [33] 59DLCL 
31PML 
Mills et al, [23] 107 
Caballero et al. [30] 366 
OS 
OS 
OS 
EFS~c 
OS 
EFS 
OS 
1/30~ 12/20~ 
29% 55% 
8% 63% 
22% 54% 
32% 50% 
10% 56% 
4% CRI 71% 
CR2 55% 
SD 46% 
25% 
*SCT indicates hematopoietic stem cell transplantation; OS, overall survival; EFS, event-free survival; DLCL, diffuse large cell B-cell non- 
Hodgkin's lymphoma; PML, primary mediastinal DLCL; CR, complete remission; SD, sensitive disease. 
tRaw data were presented for individual patients; Kaplan-Meier survival percentages were not stated in the article. 
SMedian survival times: 4.512 y for chemo-sensitive relapsed patients; 0.178 for chemo-resistant relapsed/refracto W patients (P < .001). 
compared with those who received PBSCs (10% versus 
12%). In the good-prognosis group, patients who received 
autologous PBSCs had an improved 3-year EFS compared 
with those who received autologous BM (70% versus 32%; 
P < .008). 
Stem Cell Mobilizatiotz. A variety of mobilization regi- 
mens have been used for several disease indications. Following 
are data on 3 regimens that have been analyzed specifically 
in DLCL  patients, 
Petit et al. treated 14 resistant/relapsed NHL patients 
(12 DLCL)  with etoposide, methylprednisolone, high-dose 
cytarabine, and cisplatin (ESHAP) and G-CSF for PBSC 
mobilization [37]. This feasibility study demonstrated that 
this regimen could effectively mobilize PBSCs with few (1-2) 
aphereses and low toxicity in most patients. 
Donato et al. treated 36 relapsed/primary efractory 
NHL  patients with high-dose ifosfamide, etoposide, and 
G-CSF for PBSC mobilization with minimal toxicity [38]. 
A median of 2 collections yielded CD34 + cells of greater 
than 4 x 106/kg. Median time to neutrophil engraftment 
after PBSCT was rapid for 15 patients receiving their first 
transplant (10 days) and 16 patients receiving their second 
transplant (9 days). 
Haioun et aI. demonstrated that the addition of stem cell 
factor (SCF) to cyclophosphamide/G-CSF mobil ization 
increased the number of patients who achieved a sufficient 
Table 6. Compariso*~ ofDisease-Free orProgression-Free Survival by Dhease Status at Time of SCT* 
Disease-Free or Progression-Free Survival 
Number of 
Reference Patients 2 y 3 y 4 y 5 y 6 y 
Kaplan-Meier Survival Percentages 
Resistant Chemo-sensitive Untested 
Relapse/Refractory Relapse Relapse 
Gribben et al. [27] 50 DF$ 0/3~ 
Stiff et al. [24] 94 PFS 22% 
Santini et al. [25] 54 PFS I 1% 
Philip et al. [29] 100 DFS RR- 14% 
Ref-0% 
Saez et al. [22] 45 DFS 8% 
Gulati et al. [28] 35 DFS 13% 
Wheeler et al. [26] 78 FFP 
Popat et al. [33] 59DLCL DFS 32% 
31PML 
Mills et al. [23] 107 PFS 13% 
Sehn et al, [32] 35PML PFS 33% 
Caballero et al. [30] 366 PFS 38% 
6/11r 
42% 
53% 
36% 
56% 
CR-70% 
PR-62% 
58% 
50% 
49% 
75% 
CR1-76% 
CR2-50% 
SD-38% 
13% 
>49% 
*SCT indicates hematopoietic stem cell transplantation; DFS, disease-free survival; PFS, progression-free survival; RR, resistant relapse; Ref, 
refractory; CR, complete remission; PR, partial remission; FFP, freedonl from progression; DLCL, diffuse large cell B-ceil non-Hodgkin's iym- 
phoma; PML, primary mediastinal DLCL; SD, sensitive disease. 
SRaw data were presented for individual patients; Kaplan-Meier survival percentages were not stated. 
314 
Review of SCT for DLCL 
CD34 + cell yield (12 x 106 CD34/kg) with a reduced number 
of aphereses tosupport high-dose therapy with SCT [39J. 
HLA-Matched Sibling Allogeneic Transplantations. A ret- 
rospective analysis of outcomes and prognostic factors in 
64 patients who underwent matched sibling-donor trans- 
plantations was conducted by van Besien et al. [40]. 
Among these patients, 14 were intermediate-grade NHL 
(93% DLCL), the majority of whom (n = 13) had refrac- 
tory disease or more than 1 relapse (median number of 
prior regimens, 3). All intermediate-grade patients were 
treated with cyclosporine for graft-versus-host disease 
(GVHD) prophylaxis; 5 of 14 had TBI-containing condi- 
tioning regimens, and 71% had a Karnofsky Performance 
Status (KPS) _>80. Half of the intermediate-grade NHL 
patients died of regimen-related toxicity (7/14), 4 patients 
died of progressive disease, 1 of infection, and l of 
GVHD. With a median follow-up of 38 months, the 2- 
year OS and DFS were 21% and 0% for this population of 
DLCL patients. 
Autologous GUHD. In an attempt o lower the relapse 
rate after autologous BMT, Gryn et al. treated 40 refrac- 
tory/relapsed DLCL patients with cyclosporine and inter- 
feron after autologous BMT to induce autologous GVHD 
[41]. Fifty-three percent of the patients developed grade I
GVHD (erythroderma) t a median of 20 days following 
BMT; the GVHD lasted a median of 10 days and resolved 
without treatment in all cases. After a median follow-up of 
24 months, 10% died of regimen-related toxicities, 13% 
relapsed, and the 2-year DFS was 77%. No patients devel- 
oped chronic renal insufficiency and none died of renal 
complications. Multivariate analysis could not identify any 
significant predictors of relapse. 
The evidence for SCT in these patient populations i
smnmarized in Table 7. 
C.  Untes ted  Re lapse  
The data regarding transplantation for patients with 
untested relapsed isease are not consistent and probably 
reflect differences in patient selection criteria among treat- 
ment centers. One study found that patients undergoing 
transplantation with untested relapsed isease have similar 
DFS when compared with patients with chemotherapy- 
sensitive relapse [23J; another study found similar results 
with chemotherapy-resistant relapse [22]. There is evidence 
that treatment with 3 or more regimens prior to transplan- 
tation increases the risk of adverse outcomes. Salvage 
chemotherapy before SCT to determine chemotherapy 
sensitivity in relapsed patients, however, may help define 
patient prognosis. Some investigators assume that if there 
was a long duration of CR, then the disease is sensitive, and 
they proceed to SCT in untested relapse. The time interval 
between relapse and SCT is used variably to test for prog- 
nosis, to select for transplantation only patients with 
chemotherapy-sensitive d s ase, to locate a donor for allo- 
geneic transplantation, or to allow time for insurance 
approval. There are no data to support or disprove the effi- 
cacy of testing relapsed isease for chemotherapy sensitivity 
before proceeding to SCT. 
Table 7. Grading Summa U of the Evidence 3'br SCT in Ct~emotherapy-Re,ristant Rel psed/Prima,y Refi-acto U Disease* 
Strength of Evidence t 
Quality of Median No. of 
Reference Evidence t OS EFS DFS Follow-up, mo Patients ALCL IWF F/G/H 
Armitage et al. [20] 2-3 NC NC NC MS 29 0% 100% 
Vose et al. [21 ] 2- I NC NC NA 32 25 0% 88% 
Saez et al. [22] 2- I NC NA NC 56 33 0% FIG 91% 
I0 H 50% 
Mills et al. [23] 2-3 NC NC NC 29 107 0% 85% 
Stiff et al. [24] 2- I NC NC NA NS 94 0% 76% 
Santini et al. [25] 2-1 NC NC NC 37 54 4% 89% 
Wheeler  et al. [26] 2- I NC NA NC 19 70 0% 83% 
Grlbben et al. [27] 2-1 NC NA NA NS 50 0% 82% 
Gulati et al. [28] 2-1 NC NA NC 42 44 0% 70% 
Philip et al. [29] 2-2 NC NC NC 33 100 0% 77% 
Caballero et al. [30] 2-3 NC NA NC NS 366 NS 80% 
Horning et al. [3 I] 2-1 NC NC NC 30 72 0% 71% 
Sehn et al. [32] 2-2 NC NA I 47 35 0% 100% 
Popat et al. [33] 2-2 2 NA 2 32 90 0% 100% 
Kewalramani et al. [34] 2-2 NC NC NA 35 NS 0% 84% 
Mundt et al. [35] 2-1 NA NA NC 20 53 0% 93% 
rose et al. [36] 2-2 NA I NA  21 158 0% 84% 
Petit et al. [37] 2-1 NC NC NC NS 14 0% 86% 
Donato et al. [38] 2-1 NA NA NA NS 36 I I% 81% 
Haioun et al. [39] 2- I NC NC NC NS NS NS 71% 
van Besien et al. [40] 2-2 NC NA NC 38 14 0% 93% 
Gryn et al. [41] 2-1 NA NA NC 24 40 0% 100% 
*SCT indicates hematopoietic stem cell transplantation; OS,overall survival; EFS, event-free survival; DFS, disease-free survival; ALCL, anaplas- 
tic large cell lymphoma; IWF, International Working Formulation; F, diffuse mixed cell; G, diffuse large cell; H, diffuse large cell immunoblastic; 
NC, no comparison in study between high-dose chemotherapy with SCT and standard chemotherapy; NA,not applicable; NS, not stated. 
fSee Tables 1 and 2 for definitions. 
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Figure 3. Estimated isease-free survival according to randomized consolidation procedure for the 3 risk subgroups defined by age-adjusted Inter- 
national Index. A, Low-risk group (P = .42). B, Low-to-intermediate-risk group (P = .63). C, High-to-intermediate-risk and high-risk groups (P = 
.07). Of those who received sequential chemotherapy ( - - ) ,  patients at risk were n = 43 (A), n = 96 (B), and n = 95 (C); relapses or deaths were n = 9 
(A), n = 38 (B), and n = 52 (C); 3-year estimates ofpatients at risk were 73 % (A), 58 % (B), and 41% (C). Of those who underwent autologous bone 
marrow transplantation ( ..... ), patents at risk were n = 44 (A), n = 78 (B), and n = 108 (C); relapses or deaths were n = 13 (A), n = 32 (B), and n = 42 
(C); 3-year estimates were n = 70% (A), n = 56% (B), and 60% (C). Reprinted with permission from Itaioun C, Lepage E, Gissclbrecbt C, eta]. 
Comparison of autologous bone marrow transplantation with sequential chemotherapy forintermediate-grade ndhigh-grade non-Hodgldn's lym- 
phoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Aduhe. J Clin Oncol. 1994;12(12):2543-2551. 
V. F IRST  COMPLETE REMISS ION AFTER FULL-COURSE 
STANDARD INDUCTION THERAPY 
Two pi lot studies demonst rated  the feasibil ity of 
performing BMT in DLCL patients in first CR [42,43]. The 
LNH87-2 randomized muhicenter study by Haioun et al. 
enrolled 1043 patients under age 55 with newly diagnosed 
intermediate- or high-grade NHL  who met at least one of 
the following criteria: ECOG performance status 2 to 4, >2 
extranodal sites, tumor burden of _>10 cm in largest dimen- 
sion, BM or central nervous ystem (CNS) involvement, and 
Burkitt or lymphoblastic subtypes with no BM or CNS 
involvement [44-46]. A total of 916 eligible patients received 
standard induction chemotherapy. Among these patients, 520 
achieved CR, and 464 were randomized to receive high-dose 
therapy with CBV followed by autologous BMT (n = 230) or 
sequential chemotherapy  with ifosfamide, etoposide, 
asparaginase, and cytarabine (n = 234). At median follow-up 
of 28 months, there was no statistically significant difference 
in the 3-year OS (71% chemotherapy versus 69% BMT; P = 
.60) or DFS (52% chemotherapy versus 59% BMT; P = .46 
[Figure 3]) [44]. 
Two subsequent publications presented a retrospective, 
unplanned subset analysis of the 236 high-intermediate/ 
high-risk IPI patients who achieved CR after induction ther- 
apy and were randomized. At median follow-up of 54 months 
in this subset, there was a statistically significant benefit in 
the BMT arm with respect o DFS but not OS (P = .06 ben- 
efiting the BMT arm [Figure 4]) [45]. Furthermore, at a 
median follow-up of 8 years, patients in the BMT arm had 
higher rates of DFS (55% versus 39%; P = .02) and OS (64% 
versus 49%; P = .04 [Figure 5]) [46] compared with patients 
who received sequential chemotherapy without BMT. 
Stahel et al. performed a prospective multicenter trial of 
risk-adapted therapy for DLCL  patients [47]. High-risk cri- 
teria (defined in 1991 before the IPI) included DLCL  stage 
III to IV or mediastinal DLCL  stage II to IV,, and an ele- 
vated LDH level, and/or 1 lesion >10 cm. Patients with 
high-risk DLCL  in first CR (n = 31) after etoposide, dox- 
orubicin, cyclophosphamide, vincristine, prednisone, and 
bleomycin (VACOP-B) • 12 were treated with CBV condi- 
tioning and autologous PBSCT or BMT. Patients with low- 
risk DLCL received VACOP-B x 12 followed by involved 
field radiotherapy as consolidation (n = 51). Twenty-nine 
percent of the high-risk group did not receive SCT  or 
BMT as intended because of insuff ic ient response to 
VACOP-B (n = 6), patient refusal (n = 2), pulmonary toxic- 
ity to VACOP-B (n = 1) and death during VACOP-B (n = 
1). Of  the high-risk group, 84% were identified retrospec- 
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Figure 4. Estimated survival according to randomized consolidation 
procedure for high-intermediate- and high-risk patients. Of those who 
received seqnentiai chemotherapy ( - - ) ,  patients at risk were n = 111; 
the 5-year estimate was 52%. Of those who underwent autologous 
bone marrow transplantation ( ..... ), patients at risk were n = 125; 
5-year estimate was 65%. P = .06. Reprinted with permission from 
Haionn C, Lepage E, Gisselbrecht, et ai. Benefit of autologous bone 
marrow transplantation ver sequential chemotherapy in poor-risk 
aggressive non-I{odgkin's lymphoma: updated results of the prospec- 
tive study LNH87-2. Groupe d'Emde des Lymphomes de l'Adulte..y 
Clin Oncol. 1997;15:1131-1137. 
Figure 5. Estimated survival according to randomized consolidation 
procedure for the high-intermediate- and high-risk patients. Of those 
who received sequential chemotherapy ( - - ) ,  patients at risk were n = 
111; 8-year estimate was 49%. Of those who underwent autologons 
bone marrow transplantation ( ..... ), patients at risk were n = 125; 
8-year estimate was 64%. P = .04. Reprinted with permission from 
Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high 
dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final 
analysis of the prospective LNH87-2 Protocol. A Groupe d'Etude des 
Lymphomes des l'Adulte study. J Clin Oncol. 2000; 18:3025- 3030. 
tively as high-intermediate/high-risk IPI; of the low-risk 
group, 96% were identified as low/low-intermediate-risk 
IPI. At median follow-up of 46 months, the 3-year EFS was 
76% for the low-risk and 55% for the high-risk group (P = 
.061) by intent-to-treat nalysis. OS was significantly higher 
in the low-risk group (83 % versus 53 %; P = .005). 
A retrospective cohort study by Bouabdallah et al. found 
that 60 patients treated with BMT in first CR or PR had a 
significantly improved OS, DFS, and EFS when compared 
with 66 standard chemotherapy atients [48]. At a median 
follow-up of 63 months, patients in the BMT group had a 
significantly higher 5-year OS (76% versus 31%; P < .0001), 
EFS (64% versus 24%; P < .0001) and DFS (76% versus 
42%; P = .002) compared with the standard chemotherapy 
group. The patients were well-matched based on lymphoma 
histology, sex, performance status, Ann Arbor (AA) stage, and 
IPI. The standard chemotherapy group, however, had a 
higher proportion of patients with an elevated LDH level 
(82% versus 63%; P = .01) and older age (median 51 years 
versus 43 years; P = .02), both of which are known poor prog- 
nostic factors. 
THE EVIDENCE FOR TRANSPLANTATION IN FIRST 
COMPLETE REMISSION 
There are 11o prospective studies comparing the condi- 
tioning regimens, stem cell mobilization techniques, tem 
cell source, or donor type for DLCL patients in first CR. 
The trial by Haioun et al. [44-46] used CBV as the condi- 
tioning regimen, stem cells harvested from BM, and autolo- 
gous donors. This work provides the only evidence of SeT  
in first CR that has been methodologically evaluated in com- 
parison to standard chemotherapy regimens. It is not known 
if outcomes in first CR, high-intermediate/high-risk IPI 
DLCL patients might be improved using allogeneic donors, 
nonmyeloablative or alternative conditioning and/or stem 
cell mobilization regimens, or immunotherapy following 
transplantation. These are areas of possible future research. 
The evidence for SeT  in first CR is summarized in 
Table 8. 
VI. ABBREVIMED STANDARD INDUCTION THERAPY 
(<6 COURSES OF CHOP OR <12 COURSES OF VACOP-B 
OR MACOP-B) 
Gherlinzoni et al. performed a multicenter randomized 
trial comparing methotrexate, doxorubicin, cyclophosphamide, 
vincristine, prednisone, and bleomycin (MACOP-B) x 12 
(n = 75) versus MACOP-B x 8 followed by autologous set  
with BEAC conditioning (n = 75) as front-line therapy [49]. 
Eligible patients had 2 or 3 risk factors by age-adjusted IPI 
(Aa-IPI). The interval between the end of MACOP-B x 8 
and SeT  was less than 4 weeks. Forty percent (30/75) of the 
patients did not undergo SeT  as planned, primarily due to 
disease progression. By intent-to-treat nalysis, there was no 
significant difference between the 2 groups with respect o 
PFS, relapse-free survival, or OS. 
Verdonck et al. randomized 69 patients with no BM 
involvement and a PR after 3 courses of induction with 
CHOP to receive ither 5 additional courses of CHOP (n = 
35) or autologous BMT (n = 34) with CT conditioning [50]. 
PR was defined as a reduction by at least 25 % of the sum of 
the largest umor diameters. Only 1 patient in each study 
arm was in the high-risk IPI group; 56% of patients in each 
study arm were at low or low-intermediate IPI risk. At 
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Tab le  8. Grading Summa' U of the Evide~ce r SCT in Fi'rst Complete Rem#sion * 
Strength of Evidence~ 
Quality of 
Reference Evidence~ OS EFS 
Median No.  of 
DFS Fol low-up, mo Patients ALCL  IWF F /G/H  
Gaspard et al. [42]  2- I NC NC NC 15 15 0% 80% 
Nademanee et al. [43] 2-1 NC NC NC 34 20 0% 70% 
Haioun et  al. [44]  I 3 3 3 28 464 8% 69% 
Haioun et al. [45]  I 2 NA I 54 236 9% 73% 
Haioun et  al. [46]  I I NA  I 96 236 9% 73% 
Stahel et  al. [47]  2- I  I 2 NA 46 82 12% 76% 
Bouabdul lah et al. [48] 2-2 I I I 63 126 16% 73% 
*SCT indicates hematopoietic stem cell transplantation; OS,overall survival; EFS, event-free survival; DFS, disease-free survival; ALCL, 
anaplastic large cell lymphoma; IWF, International Working Formulation; F, diffuse mixed cell; G, diffnse large cell; H, diffuse large cell 
imnmnoblastic; NC, no comparison in study between high-dose chemotherapy with SCT and standard chemotherapy; NA,not applicable. 
)See Tables l and 2 for definitions. 
median follow-up of 3 years, there was no significant differ- 
ence between the CHOP and BMT groups with regards to 
rate of CR (74% versus 68%), 4-year DFS (72% versus 
60%), 4-year EFS (53% versus 41% [Figure 6]), or 4-year 
OS (85% versus 56%). 
In a companion study to the Verdonck et al. clinical 
trial, Uyl-de Groot et al. simultaneously collected economic 
data comparing the costs associated with autologous BMT 
with the costs of standard chemotherapy [51]. The mean 
costs associated with standard chemotherapy in the treat- 
ment period were significantly less than those in the BMT 
group (US $ 3,118 versus US $ 34,447; P < .01), but the aver- 
age costs in the 2-year follow-up period were not significantly 
different between the groups (standard chemotherapy, 
US $12,436 versus BMT, US $15,837; P = NS). A compari- 
son of long-term costs in a follow-up period of 8 years 
found higher but not statistically significant costs associated 
with BMT (US $56,512) compared to standard chemo- 
therapy (US $20,397). The discounted life years (LYs) and 
qualhy-adjusted life years (QALYs) for BMT (LYs, 4.49; 
QALYs, 3.84) were lower than for standard chemotherapy 
(LYs, 5.04; QALYs, 4.33). 
Martelli et al. performed a multicenter randomized trial 
comparing conventional full-course induction chemotherapy 
(MACOP-B x 12 weeks) with a similar but abbreviated 
induction regimen followed by PBSCT (MACOP-B x 
8 weeks, autotransplantation with BEAC conditioning) [52]. 
All 109 newly diagnosed patients had 2 to 3 risk factors by 
age-adjusted IPI. Preliminary intent-to-treat nalysis at 
median follow-up of 25 months demonstrated nostatistically 
significant difference in OS or PFS between the full-course 
induction chemotherapy arm and the abbreviated induc- 
tion/PBSCT arm. Nearly half of the patients (46%) random- 
ized to the abbreviated induction/PBSCT arm did not 
receive transplants due to progressive disease (33%), prior 
toxicity (38%), or patient refusal (29%). This study contin- 
ues to accrue patients; forthcoming analyses with additional 
patients and more mature follow-up are anticipated. 
A multicenter study by Reyes et al. did not meet this 
review's criterion of including 70% DLCL patients (69% of 
patients were DLCL). The study is noteworthy, however, 
for also evaluating an abbreviated induction course and 
autotransplantion compared to a more standard regimen 
[53]. Poor-risk intermediate- or high-grade NHL patients 
were randomized to receive either full-course induction 
therapy with ACVB (doxorubicin, cyclophosphamide, vin- 
desine, bleomycin, and prednisolone) followed by sequential 
consolidation, or an abbreviated induction regimen followed 
by PBSCT with BEAM conditioning. The abbreviated 
induction regimen consisted of 1 cycle of CEOP (cyclo- 
phosphamide, pirubicin, vincristine, and prednisone) and 
2 cycles of ECVBP (epirubicin, cyclophosphamide, vinde- 
sine, bleomycin, and prednisone). Analysis of 370 eligible 
patients at median follow-up of 30 months howed a signifi- 
cantly better 3-year EFS (54% versus 41%; P = .01) and OS 
(63% versus 47%; P = .003) for the conventional chemo- 
therapy group compared to the abbreviated induction/ 
PBSCT group. There was no significant difference in CR or 
treatment-related mortality between the 2 groups. Of 
patients randomized to the abbreviated induction/PBSCT 
group, 29% did not proceed to transplantation, primarily 
due to disease progression. 
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Figure 6. Event-free survival from the time of randomization, accord- 
ing to treatment group. Among 35 patients assigned toreceive 8courses 
of CHOP and 34 patients assigned to receive high-dose chemoradio- 
therapy and autologous bone marrow transplantation, there were 15 and 
18 treatment failures, respectively. Reprinted with permission from 
Verdonck LF, van Putten WLJ, Hagenbeek A, et al. Comparison of
CHOP chemotherapy with autologous bone marrow transplantation 
for slowly responding patients with aggressive non-Hodgkin's lym- 
phoma. NEnglffMed. 1995;332:1045-1051. Copyright 9 1995 Massa- 
chusetts Medical Society. All rights reserved. 
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Intragumtornchai  et al. randontized DLCL  patients 
under age 55 (65% were high-risk AalPI) after 3 courses of 
CHOP to receive either continued CHOP therapy (n = 25) 
or 2 to 4 courses of ESHAP followed by PBSCT (n = 23) 
[54]. At median follow-up of 12 months, the PBSCT group 
had significantly higher rates of freedom from progression 
(FFP) (64% versus 25%; P = .008), freedom from relapse 
(91% versus 37%; P = .05) and EFS (33% versus 13%; P = 
.05) compared to the CHOP group. There was no signifi- 
cant difference between the 2 groups in OS (34% versus 
32%; P = 0.83). 
The evidence for SCT after abbreviated induction ther- 
apy is summarized in Table 9. 
VI I .  M IXED DISEASE RESPONSES TO INDUCTION 
THERAPY 
Santini et al. randomized newly diagnosed, untreated 
patients with stage II bulky (_>10 cm), stage III, or stage 1V 
diffuse intermediate- or high-grade NHL to receive either 
VACOP-B for 12 weeks followed by DHAP as a salvage 
regimen (n = 61) or VACOP-B for 12 weeks followed by 
autologous BMT with BEAM conditioning (n = 63) [55]. 
Patients proceeded to BMT regardless of response to 
VACOP-B.  All results were presented as intent-to-treat 
analyses. At median follow-up of 42 months, there was no 
significant difference between the groups in response rate 
or in 6-year DFS, PFS, or OS (Figure 7). Of  patients ran- 
domized to the BMT arm, 29% did not undergo the proce- 
dure due to ineligibility, death during induction, patient 
refusal, or disease progression. Retrospective analysis by 
IPI  showed a significantly improved 6-year DFS (87% ver- 
sus 48%; P = .008) and a trend toward improved 6-year 
PFS (65% versus 37%; P = .08) for high-intermediate- and 
high-risk IPI  groups in the BMT arm, with no difference in 
6-year OS (65% versus 65%; P = .5) compared to patients 
in the non-BMT arm. 
Fanin et al. compared outcomes of autologous SCT  
among patients in the 3 major subtypes of DLCL  (centro- 
blastic, immunoblastic, and anaplastic), and by disease status 
at the time of transplantation [56]. The following character- 
istics were seen among 797 patients: 53.5% had low- or low- 
intermediate-risk IPI; first CR 27.7%, _> second CR 17.3%; 
PR 26. i %; sensitive relapse 8.7 %; relapse/refractory 15%. 
Significant prognostic factors by multivariate analysis for 
PFS were disease status at SCT  (P < .0001) and IPI  score 
(P < .008). Histology subtype (centroblastic versus immuno- 
blastic versus anaplastic), stage, B symptoms, age, sex, and 
conditioning regimen were not significant predictors of PFS. 
Conde et al. reported on 39 patients who underwent 
transplantations for mediastinal DLCL  with sclerosis [57]. 
Seven patients had BMT; 32 had PBSCT. Conditioning reg- 
imens were BEAM (n = 16), BEAC (n = 11), CT  (n = 5), and 
others (n = 7). The OS by disease status at time of SCT was 
first CR, 78%; second CR, 75%; stable disease, 47%; resis- 
tant disease, 12%. Median time to relapse was 7.5 months. 
THE EVIDENCE FOR TRANSPLANTAT ION IRRESPECTIVE OF 
DISEASE STATUS 
Allogeneic BMT 
Dhedin et al. studied a group of 73 patients (71% 
DLCL)  who underwent allogeneic BMT from an HLA-  
matched sibling or (in 1 patient) an HLA-matched unrelated 
donor [58]. Ten patients had a prior autologous BMT and 
the median number of prior therapies was 2. Among all 
patients, 34% were in CR >i, 29% were in PR >1, and 37% 
had refractory disease. At median follow-up of 90 months, 
the 5-year OS and PFS were 41% and 40%, respectively. A 
total of 16 patients relapsed, all in the first 15 months, 
except 1 patient who relapsed at 7 years post-BMT. Multi- 
variate analysis of factors predictive for survival found that 
patients who received fewer than 3 pretransplantat ion 
chemotherapy regimens (relative risk [RR] = 20.8; P = .04) 
and were in CR at time of BMT (RR = 4.043; P < .0001) had 
significantly prolonged survival. Patients who underwent 
transplantations while in CR had a lower risk of disease pro- 
gression post-BMT (P = .01) and fewer toxic deaths (P = .01) 
compared with patients who were not in CR at time of 
BMT. Five-year OS in 25 patients who underwent rans- 
plantations while in CR was 76% compared with 23% in 
48 patients not in CR at BMT (P < .0001). Age, sex, BM or 
CNS involvement at diagnosis, disease stage at diagnosis, 
immunophenotype,  prior autologous BMT, response to 
induction therapy, BM involvement at time of transplanta- 
tion, and disease sensitivity at time of transplantation were 
not significant predictors of survival by multivariate analysis. 
The Role of BM Involvement 
Bolwell et al. retrospect ive ly  reviewed 147 DLCL  
patients who underwent PBSCT to compare outcomes of 
patients with and patients without bone marrow involve- 
ment [59]. No BM involvement during disease course was 
Table 9. Grading Summa U of the Evidence for SCT After Abb'reviated b*dz~ctio77 The~'apy * 
Strength of Evidence~ 
Quality of 
Reference Evidence~ OS EFS DFS 
Median No. of 
Follow-up, mo Patients ALCL IWF F/G/H 
Gherlinzoni et al. [49] I NC NC 3 34 150 9% 77% 
Verdonck et al. [50] I 3 3 3 36 69 0% 71% 
Martelli et al. [52] I 3 NC 3 25 109 14% 73% 
Reyes et al. [53] I 5 5 NC 30 370 NS 69% 
Intragumtornchai et al. [54] 4 3 I I 12 58 NS 78% 
*SCT indicates hematopoietic stem celI transplantation; OS, overall survival; EFS, event-free survival; DFS, disease-free smwival; ALCL, 
anaplastic large cell lymphoma; IVVF, International Working Formulation; F, diffuse mixed cell; G, diffuse large cell; H, diffuse large cell 
imnmnoblastic; NC, no comparison i study between high-dose chemotherapy with SCT and standard chemotherapy; NS, not stated. 
~See Tables I and 2 for definitions. 
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Figure 7. Estimated 6-year overall survival, disease-free survival (DFS), and progression-free survival (PFS) according to treatment arm (arm A, 
VACOP-B [etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin]; arm B, VACOP-B plus ABMT). Reprinted with 
permission from Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced if- 
filse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative group, ff CliT~ Oncol. 
1998;16:2796-2802. 
seen in 113 patients (77%); 16 patients (11%) had BM 
involvement at diagnosis only; 5 patients (3%) had BM 
involvement at time of SCT only; and 13 patients (9%) had 
BM involvement at both time of diagnosis and t ime of 
transplantation. Four-year OS and EFS were not signifi- 
cantly different between these groups (Table 10). By multi- 
variate analyses, elevated LDH level (P = .002), refractory 
disease (P = .04), and >1 course of prior chemotherapy (P = 
.05) were the only significant predictors of OS and EFS. BM 
involvement was not a significant predictor for OS and EFS 
when assessed by whether there was ever BM involvement 
as well as by time of BM involvement. 
Evidence for SCT  irrespective of disease response to 
induction therapy is summarized in Table 11. 
VIII. UP-FRONT HIGH-DOSE INDUCTION THERAPY IN 
NEWLY DIAGNOSED UNTREATED PATIENTS 
A.  H igh-Dose  Sequent ia l  Therapy  in High- 
I n te rmed ia te /H igh-R isk  IP I  Pat ients  
In a multi-institution study, Gianni et al. randomized 
98 patients with no BM involvement and a high-intermedi- 
ate- or high-risk IPI  to receive either MACOP-B (n = 50) 
or high-dose sequential (HDS) therapy (n = 48) [60]. A 
cross-over study design allowed patients who failed one 
treatment to receive subsequent treatment with the other. 
Patients in the MACOP-B arm received a 12-week course. 
HDS patients received a 4-phase treatment schedule con- 
sisting of a 21-day induction regimen, stem cell mobilization 
with high-dose cyclophosphamide plus a colony-stimulating 
factor, followed by BM and/or PBSC collections, and a 
4-day consolidation phase. Lastly, SCT was performed with 
either TBI,  etoposide, and melphalan (n = 30); or mitox- 
antrone, etoposide, and melphalan (n = 18) as conditioning. 
The HDS therapy arm had a significantly better 7-year EFS 
than the MACOP-B arm (76% versus 49%; P < .004 [Figure 
8]). The 7-year OS in the HDS therapy arm showed a trend 
toward a signif icant difference when compared to the 
MACOP-B arm (81% versus 55%, P = .09). 
Vitolo et al. reported an ongoing multicenter trial of 
HDS therapy plus autologous SCT (n = 46) compared with 
an intensified regimen of MegaCEOP (cyclophosphamide 
[1200 m~/m 2] epi rubic in  [110 rag/m2], v incr is t ine 
[1.4 mg/m ], and prednisone [40 mg/m2]) (n = 53) in DLCL  
patients [61]. Of  the patients, 65% had an high-intermedi- 
Table I 0. Summary of Overall a*zd Evem-Free Sw~oival by Bolee Maf'wow 
Involvement [59]* 
BM Involvement 4-year OS (P = .29) 4-year EFS (P = .42) 
Never 52% 40% 
At SCT 80% 80% 
At Diagnosis 74% 47% 
Both 83% 61% 
*BM indicates bone marrow; OS, overall survival; EFS, event-free 
survival; SeT, hematopoietic stem cell transplantation. 
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Table I I .  Grading Summary ofthe Evidence for SC7'I'm'e;pective of Disease Response to IT,~d'uctiolz Therapy* 
Strength of Evidence~ 
Quality of Median 
Reference Evidence~ OS EFS DFS Follow-up, mo 
No. of 
Patients ALCL IWF F/G/H 
Santini et al. [55] I 3 NA 3 42 124 10% 83% 
Fanin et al. [56] 2-2 NC NC NC NS 420 12% 88% 
Conde et al. [57] 2-2 NC NC NC 20 39 NS 100% 
Dhedin et al. [58] 2-3 NC NA NC 90 73 18% 71% 
Bolwell et al. [59] 2-2 NC NC NC NS 147 NS 100% 
*SCT indicates hematopoietic stem cell transplantation; OS, overall survival; EFS, event-free survival; DFS, disease-free survival; ALCL, 
anaplastic large cell lymphoma; IWF, International Working Formulation; F, diffuse mixed cell; G, diffuse large cell; H, diffuse large cell 
immtmoblastic; NC, no comparison i study between high-dose chemotherapy with SCT and standard chemotherapy; NS, not stated. 
tSee Tables 1 and 2 for definitions. 
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Figure 8. Kaplan-Meier plots of freedom from disease progression, freedom from relapse, event-free survival, and overall survival for 48 patients 
initially assigned to high-dose sequential therapy (HDS) and 50 assigned to MACOP-B. The initial number of patients in complete remission and 
at risk for relapse was 46 for HDS and 35 for MACOP-B. The median follow-up was 55 months. The nmnber of patients at risk is shown below 
each time point. Percentages atright are for each category of survival (free from disease progression, free from relapse, event-free, and overall) at 
7 years. Reprinted with permission from Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplanta- 
tion compared with MACOP-B in aggressive B-cell lymphoma. N EnglJ Med. 1997;336:1290-1297. Copyright 9 1997 Massachusetts Medical 
Society. All rights reserved. 
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ate-risk IPI score and 35 % had a high-risk-IPI score. The 
HDS regimen consisted of adriamycin, vincristine, and pred- 
nisone followed by intensification with cyclophosphamide, 
methotrexate, vincristine, and etoposide with or without 
2 DHAP courses in patients with BM involvement. The 
HDS regimen was followed by autologous SCT conditioned 
with mitoxantrone and melphalan. MegaCEOP was given 
for 6 courses in BM-negative patients and for 8 courses in 
BM-positive patients. One patient in the HDS/SCT arm and 
2 in the MegaCEOP arm died of toxicity. Six patients in the 
HDS/SCT arm and 5 in the MegaCEOP arm did not com- 
plete therapy due to toxicity or progression. Similar rates of 
CR were observed in both groups; however, patients with 
high-risk IPI had a significantly lower rate of CR than those 
with high-intermediate-risk IPI (49% versus 69%; P < .02). 
This study closed to accrual in December 1999 and is ongo- 
ing for survival analyses. 
Cortelazzo et al. assessed 2 consecutive cohorts of previ- 
ously untreated DLCL patients younger than 60 years of age 
to compare MACOP-B x 12 (n = 60) with MACOP-B x 8, 1 
to 2 cycles of mitoxantrone, cytarabine, and dexamethasone 
(MAD) intensification and PBSCT or BMT with BEAM 
conditioning (n = 61) [62]. Therapy was completed by 85% 
of the patients in each group. Median follow-up of surviving 
patients was 37 mdnths for the transplantation cohort and 
87.5 months for the standard chemotherapy cohort. By 
intent-to-treat nalysis, the transplantation group had a 
higher rate of response (CR/CR with scan abnormalities of 
unknown significance [CRu]) (84% versus 68%; P = .0491); 
a better 2-year EFS (70% versus 50%; P = .0281) and no 
difference in 2-year OS (73% versus 62%; P = .2191) com- 
pared with the standard chemotherapy group. 
A retrospective analysis by AaIPI demonstrated a 
significant difference in the 2-year EFS (63% transplanta- 
tion versus 40% chemotherapy group; P = .0269) in the high- 
intermediate/high-risk IPI subgroup, but no difference (2-year 
EFS, 85% transplantation versus 82 % chemotherapy group; 
P = .8297) in the low-intermediate/low-risk IPI subgroup. 
Vitolo et al. conducted a phase II study of 50 DLCL 
patients [63] who are an overlapping population with the 
Cortelazzo et al. transplantation cohort [62]. The 3-part 
HDS therapy schema consisted of MACOP-B induction for 
8 weeks, intensification with MAD plus G-CSF, followed by 
leukapheresis and autologous PBSCT with BEAM as condi- 
tioning. BM involvement was seen in 38% of the patients. 
At 32 months, OS was 56% and failure-free survival (FFS) 
was 50%. There was a trend toward better survival rates in 
patients who did not have BM involvement compared with 
those who did (3-year OS, 58% versus 53%; 3-year FFS, 
52% versus 45%). 
Stoppa et al. conducted a pilot phase II trial in 
20 untreated DLCL patients younger than 60 years of age 
with 2 to 3 IPI factors using 6 HDS therapy courses [64]. 
Each of the first 3 courses consisted of 1 cycle of CHOP fol- 
lowed by PBSC collection. Each of the last 3 courses con- 
sisted of 1 cycle of CHOP plus etoposide and cisplatin fol- 
lowed by reinfusion of PBSCs. Of 20 patients, 17 completed 
all 6 courses; 1 patient died of toxicity during the 6-course 
schedule. The response rate after 6 courses was 85% (65% 
CR; 20% PR). At median follow-up of 31 months, 2-year OS 
was 73%, FFS was 56%, and DFS was 86%. 
B. High-Dose Sequential Therapy in Non-IPI 
High-Risk Patients 
Milpied et al. performed a randomized trial in newly 
diagnosed patients with low- (7%), low-intermediate (38%), 
highqntermediate- (48%) and high- (7%) risk IPI patients 
under age 60 [65]. Results of 8 cycles of CHOP every 
21 days were compared with those of an HDS therapy regi- 
men consisting of CEEP (cyclophosphamide, epirubicin, vin- 
desine, and prednisone) for 2 cycles every 15 days with gran- 
ulocyte macrophage colony-stimulating factor (GM-CSF) 
support, PBSC collections after the first or second course of 
CEER followed by 1 course of high-dose methotrexate and 
cytarabine, and PBSCT with BEAM conditioning. 
In an intent-to-treat analysis at 22-month median follow- 
up, OS was 51% for CHOP versus 76% for PBSCT 
(P > .1); EFS was 38% for CHOP versus 59% for PBSCT 
(P = .03) and FFP was 40% for CHOP versus 60% for 
PBSCT (P = .05). Subanalysis showed a better OS in high- 
intermediate-risk IPI patients in the PBSCT arm (3-year 
OS, 78% versus 43%; P = .01). 
A feasibility study of a 3-phase HDS therapy trial for 
40 patients with BM involvement was performed by Santini 
et al. [66]. Half of the patients had a low-intermediate-risk 
IPI score (1 factor). Patients were given induction therapy 
with VACOP-B x 8, intensification with high-dose cyclo- 
phosphamide and G-CSF followed by leukapheresis, and 
autologous PBSCT with BEAM or melphalan plus TBI as 
the conditioning regimen. The 5-year OS for the 40 HDS 
therapy patients was 42%; the DFS and FFS were 39% and 
34%, 
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12; at relapse in 4; and with refractory disease in 4. All 
patients completed both transplantations. Mitoxantrone and 
melphalan were used as conditioning for first transplanta- 
tion; etoposide and carboplatin were used for the second. At 
median fbllow-up of 3 years, 18 of 22 (82%) patients in the 
first line/consolidation group were alive and disease-free 
compared to 2 of 8 (25%) in the relapse/refractory group. 
Three patients died of relapsed or progressive disease; there 
were no deaths due to regimen-related toxicity. 
The evidence for SCT as up-front HDS in newly 
diagnosed patients i summarized inTable 12. 
IX .  RESPONSE CRITERIA  
A National Cancer Institute (NCI)-sponsored Interna- 
tional Workshop was held in 1999 to standardize r sponse 
criteria for Nt IL  [70]. The results of the evidence-based 
review of DLCL presented here emphasize the importance 
of using standard criteria for measuring response to therapy 
in NHL patients. Standardization allows for more mean- 
ingful comparisons among clinical trials. This international 
working group's study provided consensus definitions of 
CR, CRu, PR and Relapse/Progression and included efini- 
tions of normal ymph node size, bone marrow assessment, 
and endpoints for clinical trials (eg, OS, EFS, PFS). 
X.  TREATMENT RECOMMENDATIONS 
Treatment recommendations areoutlined in Tables 13 
and 14. 
Xl .  FUTURE D IRECT IONS 
A .  New Mo lecu la r  Subgroups  and  Prognost i c  Markers  
Attempts to divide DLCL into molecular subtypes have 
not been successful. Both the REAL [1] and WHO [2] classi- 
fications found incomplete vidence that division by DLCL 
subtype would point to different therapeutic options and/or 
lead to better outcomes. Several recent abstracts and a manu- 
script have further explored the area of molecular analyses 
for the identification ofnew prognostic markers and possible 
new subtypes of DLCL. These molecular analyses were con- 
ducted in newly diagnosed patients who were subsequently 
followed for varying lengths of time after standard chemo- 
therapy or high-dose chemotherapy with SCT 
The following molecular classifications have been found 
to be significant prognostic factors for survival independent 
of the IPI: germinal center expressing B cells (by DNA 
microarray technology) [71]; gene expression profiles, 
including enes related to cell origin; cell adhesion; apopto- 
sis; RAS signaling; serine/threonine phosphorylation a d 
rumor immunity (by oligonucleotide microarray technology) 
[72]; bcl-6 mutations [73]; lack of co-expression of bcl-2 and 
P-glycoprotein [74]; lack of survivin (an apoptosis inhibitor) 
expression [75]; low serum ~2-microglobulin [76,77]; and 
bcl-2 protein expression [78,79]. Factors evaluated that were 
not significant predictors independent of the IPI were low 
serum CD44 [80], p53 mutation and p53 protein expression 
[81], number of cytogenetic aberrations [82], MIB-1 mono- 
clonal antibody against Ki-67 nuclear protein [83], bcl-2 
gene expression [78,79], and bcl-6 and MYC gene rearrange- 
ments [79]. It is likely that DLCL patients will be stratified 
by molecular classifications for clinical prognosis once there 
is better understanding of DLCL subtype gene expression. 
B. Add i t iona l  Ongo ing  Stud ies  
Transplantation Versus Standard Chemotherapy. 
The Scotland and Newcastle Group are conducting a
phase III randomized trial of high-dose chemotherapy and 
radiotherapy plus autologous BMT in patients with 
aggressive NHL (Protocol ID: SNLG-NHL-V(a), EU- 
98032). Eligible patients under age 65 are stratified by risk 
group (good versus intermediate v rsus poor) as defined by 
the investigators. 
Patients enrolled in the study undergo leukapheresis for 
the collection of autologous tein cells before induction 
chemotherapy. Patients receive induction therapy with 
CHOP or VAPEC-B (vincristine, doxorubiein, pred- 
nisolone, etoposide, cyclophosphamide, and bleomycin) fol- 
lowed by radiation therapy to areas of original bulk or resid- 
Table 12. Grad&g Sum'ma'~ 7 of the Evidence for SCT as Up-Front High-Dose [n&~ction Therapy ir~, Newly DiagT~osed Putiems* 
Strength of Evidence t 
Quality of Median No. of 
Reference Evidence t OS EFS DFS Follow-up, mo Patients ALCL  IWF FIGIH 
Gianni et al. [60] I 2 I I 55 98 0% 100% 
Vitolo et al. [61 ] I NC NC NC NS 99 0% 100% 
Cortelazzo et al. [62] 2-2 I 3 NC 35 121 I 1% 77% 
Vitolo et al. [63] 2-I NC NC NC 32 50 12% 88% 
Stoppa et al. [64] 2-1 NC NA NC 31 20 30% 70% 
Milpied et al. [65] I 3 I 2 22 168 NS 73% 
Santini et al. [66] 2- I NC NC NC 60 40 15% 85% 
Haioun et al. [67] 2- I NC NC NC 36 31 NS 78% 
Ballestrero et al. [68] 2- I NA  NC HA 24 25 8% 92% 
Clavio et al. [69] 2-1 NC NA NC 36 30 10% 90% 
*SCT indicates hematopoietic stem cell transplantation; OS,overall survival; EFS, event-free survival; DFS, disease-flee survival; ALCL, 
anaplastic large cell lymphoma; IWF, International Working Formulation; F, diffuse mixed cell; G, diffuse large cell; H, diffuse large cell 
immunoblastic; NC, no comparison in study between high-dose chemotherapy with SCT and standard chemotherapy; NA,not applicable. 
tSee Tables 1 and 2 for definitions. 
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Table 13. Treatment Recomzn, endations by Dlkease Response and International larogl~,ostic bzdex ([PI) Rl>k * (f/Vhere Available) 
Treatment Level of 
Indication for SCT in: Recommendation~ Evidencew References/I Comments 
First chemotherapy-sensitive r lapse 
Chemotherapy-resistant 
relapse/primary refractory disease 
First complete remission in 
patients With L/I-L IPI risk 
First complete remission in 
patients with H/I-H IPI risk 
First partial remission after 
full-course induction therapy 
After abbreviated induction 
therapy (<6 cycles of CHOP 
or < 12 cycles of MACOP-B 
or VACOP-B)  
As high-dose sequential therapy 
in untreated patients with 
I-H/H IPI risk 
As high-dose sequential therapy 
in untreated patients with 
L/k-I IPI risk 
i i [8-1 q 
4 2 [22-34]  
3 I [44]  
I82 2 144-46] 
4 NA 
3 82 I [50-54] 
I I 60 
4  82  I 65 
Based on results from the original analysis with 
short follow-up 
Refs 1,45-46] show a benefit for SCT based on a 
retrospective unplanned subset analysis in the 
high-risk patients only. Ref [44] demonstrates 
no benefit based on all randomized patients 
with short follow-up. 
Ref [50] used a unique definition of PR; Ref [52] is 
still accruing patients; Ref [53] significantly 
favors the standard chemotherapy arm, 
however included <70% DLCL. 
Only 45% of the patients had low or low- 
intermediate IPI risk; included 55% patients with 
high-intermediate or high IPI risk 
*See Appendix B for definitions of IPI risk models. 
tSCT indicates hematopoietic stem cell transplantation; L, low; I, intermediate; H, high; NA, no evidence available; CHOP, cyclophosphamide, 
doxorubicin, vincristine, and prednisone; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; 
VACOP-B, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin. 
$See Table 3 for definitions. 
~See Table 1 for definitions. Levels 2-1 through 2-3 were condensed as Level 2 due to the heterogeneity of study designs represented by the ref- 
erences listed and for simplicity. 
liThe references listed represent the highest level of evidence used to make the treatment recommendation a d are not inclusive of all evidence 
described in the review. 
~Treatment recommendation s based on problems in methodology ofthe study(ies). 
Table 14. Treatment Recommendations for Transplantation Techniques* 
Treatment Level of 
Procedure Indicated Recommendation~ Evidence~ Referencesw Comments 
Double/Tandem SCT 
Myeloablative allogeneic SCT 
Nonmyeloablative allogeneic SCT 
Autologous BMT 
Autologous PBSCT 
Purging 
Stem cell mobilization method 
Conditioning regimens 
As high-dose sequential therapy 
in patients with I-H/H IPI risk 
As high-dose sequential therapy 
in patients with L/L-I IPI risk 
4 2 {67-69]  
4 2 1,40,581 
4 NA 
I I 1,8- I 1 ,44-46]  
I 3 
4 2 18 
4 2 [37-39] 
4 NA 
I I [601 
4 I 1,65] 
Studies consisted of mixed population of 
untreated, relapsed, and refractory patients 
Only 45% of the patients had low or low- 
intermediate IPI risk; included 55% patients 
with high-intermediate or high IPI risk 
*SCT indicates hematopoietic stem cell transplantation; NA, no evidence available; BMT, bone marrow transplantation; PBSCT, peripheral 
blood stem cell transplantation; L, low; I, intermediate; H, high; IPI, International Prognostic Index. 
tSee Table 3 for definitions. 
~:See Table 1 for definitions. Levels 2-1 through 2-3 were condensed as Level 2 due to the heterogeneity of study designs represented by the ref- 
erences listed and for simplicity. 
w references listed represent the highest level of evidence used to make tile treatment recommendation a d are not inclusive of all evidence 
described in the review. 
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ual disease. Good-risk patients are randomized to receive no 
further treatment (arm I) or melphalan plus TBI and autolo- 
gous BMT (arm II). Intermediate- and poor-risk patients 
receive autologous BMT and are randomized to condition- 
ing with either melphalan alone (arm III), melphalan plus 
TBI (arm IV), or BEAM (arm V). This study may provide 
data for comparing the efficacy of 3 preparative regimens 
for autologous BMT in intermediate/poor-risk lymphomas, 
and the value of BMT in good-risk patients. 
The British National Lymphoma Investigation (BNLI) 
is conducting a phase III randomized study of early intensi- 
fication with autologous BMT or PBSCT versus continued 
standard chemotherapy. Eligible patients must have follicu- 
lar large cell, diffuse mixed cell, diffuse large cell, or diffuse 
immunoblastic lymphoma nd 2 to 3 Aa-IPI factors. All 
patients are treated with CHOP x 6 and then randomized to 
receive BEAM autologous BMT or PBSCT (arm I) or to 
continue with conventional chemotherapy (arm II). 
A Southwest Oncology Group (SWOG) randomized 
multicenter t ial (SWOG-9704) will compare CHOP x 6 
and autologous PBSCT in responders with CHOP x 8 cycles 
followed by autologous PBSCT only at relapse. Patients with 
intermediate- or high-grade NHL and high-intermediate/ 
high-risk Aa-IPI are eligible for the trial. This study seeks to 
provide evidence of the utility of PBSCT versus CHOP as 
primary therapy in poor-risk patients. 
The Swiss Institute of Applied Cancer Research is con- 
ducting a randomized multicenter t ial comparing sequen- 
tial high-dose chemotherapy with autologous PBSCT with a 
regimen of CHOP x 6-8 in patients with newly diagnosed 
diffuse large B-cell lymphoma, primary mediastinal large 
B-cell lymphoma, and anaplastic large cell lymphoma with 
at least 1 Aa-IPI factor. Patients in the high-dose sequential 
therapy arm receive the following 5 regimens: 
Regimen A: doxorubicin, vincristine and prednisone x 
1 cycle. 
RegimenB: 3 weeks after regimen A, high-dose 
cyclophosphamide, G-CSF, and PBSC 
collections if no BM involvement at diag- 
nosis (if BM involvement at diagnosis, 
PBSCs are not collected at this time). 
Regimen C: 2 to 3 weeks after regimen B, vincristine 
and high dose methotrexate. 
Regimen D: 1 to 2 weeks later, methylprednisone and 
high-dose toposide; patients with no BM 
involvement at diagnosis receive G-CSF 
until count recovery, patients with initial 
BM involvement receive G-CSF and 
undergo PBSC collection. 
Regimen E: autologous PBSCT with mitoxantrone and 
melphalan; patients with bulky disease at 
diagnosis or residual disease after chemo- 
therapy receive radiation therapy 30 to 100 
days after PBSCT. 
An NCI-sponsored randomized trial (NCI-V96-1010) is 
comparing the efficacy and cost-benefit of early intensifica- 
tion including autotransplantation with BEAM versus con- 
ventional-dose alternating triple chemotherapy in untreated, 
intermediate-grade or immunoblastic NHL patients at high 
risk for relapse. Eligibility requires 3 or more of the follow- 
ing: Ann Arbor stage III/IV disease, B symptoms, tumor 
mass(es) greater than 7 cm or mediastinal mass visible on 
chest x-ray, [3-2 microglobulin at least 3.0, and LDH level 
greater than 1.1 times normal. Patients in arm I receive 
induction with 1 course of idarubicin, cisplatin, cytarabine, 
and methylprednisone (IDSHAP) and 1 course of metho- 
trexate, leucovorin calcium, idarubicin, vincristine, bleomycin, 
cyclophosphamide, and methylprednisolone (MBIDCOS). 
Patients with stable or responding disease receive 3 addi- 
tional courses every 21 days consisting of 1 course of ifos- 
famide/etoposide/mesna/G-CSF (2 courses if there are 
circulating lymphoma cells) and PBSC collection, 1 course 
of ifosfamide/mitoxantrone/mesna/G-CSF and 1 course of 
BEAM conditioning for PBSC reinfusion. PBSCs are 
purged ex vivo prior to reinfusion in patients with a history 
of BM or PB involvement. Patients in arm II also receive 
induction with IDSHAP and MBIDCOS, followed by 
7 additional courses consisting of alternating courses of 
MINE (mesna, ifosfamide, mitoxantrone, etoposide), 
IDSHAP, and MBIDCOS. Each course is given upon hema- 
tologic recovery from the previous course. 
Posttransplantation Therapy 
The Groupe d'Etude des Lymphomes de l'Adulte 
(GELA) trial is a phase III randomized trial to determine 
the efficacy of interferon a-2b in reducing the relapse rate 
in patients treated with PBSCT for recurrent or refractory 
HD or NHL in second remission [84]. Eligible patients 
include those with follicular, diffuse small cell, mantle cell, 
peripheral T-cell, diffuse large B-cell, lymphoblastic, or 
Burkitt's lymphoma in second CR after autologous SCT, 
given either as first-line therapy or salvage therapy after first 
relapse. Patients are stratified by lymphoma subtype and 
randomized after PBSCT to receive either no further 
therapy (arm I), or interferon c~-2b 3 times weekly for 
18 months tarting 4 weeks after SCT (arm II). This study 
may provide evidence of the efficacy of immunotherapy 
after SCT to prevent relapse. 
A SWOG randomized multicenter t ial (SWOG 9438) 
will compare the OS and DFS of patients who receive inter- 
leukin (IL)-2 after autologous PBSCT with VCT, with 
patients who are randomized to observation and no other 
therapy post-BMT. 
C. Unanswered Questions 
Whether to have patients undergo transplantation i  
first CR or to withhold transplantation u til patients have 
demonstrated a chemotherapy-sensitive relapse after first 
CR is an important unanswered question in DLCL treat- 
ment, and one which has been examined only in a nonran- 
domized prospective trial [85]. Thirty-one patients with 
diffuse histiocytic lymphoma (30 large cell, 1 mixed cell) and 
bulky disease and/or elevated serum LDH level were given 
induction therapy with the L-17M regimen. In the original 
protocol design, patients were randomized to receive autol- 
ogous BMT in first CR/PR or to have BMT withheld until 
relapse. Patients, however, were reluctant to undergo ran- 
domization and instead preferred to choose a study arm. As 
a result, the protocol was revised and patients were allowed 
to choose up-front BMT versus BMT at relapse. 
At a median follow-up of 49+ months, 14 patients who 
elected to receive autologous BMT in first CR/PR had a 
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4-year OS of 79% compared with a 4-year OS of 24% in 
17 patients who elected to undergo autologous BMT at 
relapse. There was a significant DFS advantage (P = .002) 
for the patients who underwent transplantation in first 
remission (79% survived a median of 49+ months) com- 
pared with those who underwent transplantation at relapse 
(23 % survived a median of 5 months). This study was non- 
randomized with a small sample size, so no definite conclu- 
sions can be reached. A large randomized trial is needed to 
address the question of transplantation in first remission or 
first chemotherapy-sensitive relapse. 
D. Areas of Needed Research 
The following research questions have been identified 
by this evidence-based review and are grouped into 2 cate- 
gories: disease-related and treatment-related. Studies to 
provide clarification of these topics are ongoing or war- 
ranted. No priority was assigned, because the topics listed 
can be studied concurrently. 
Disease-Related Research Questions 
Should patients be offered SCT in first CR or wait until 
first chemotherapy-sensitive relapse? The results of ongoing 
studies are pending. 
Should patients receive salvage therapy in first relapse to 
test for chemotherapy sensitivity, or proceed to SCT in 
untested relapse? 
What is the optimal timing of SC mobilization? Should 
high-risk patients be mobilized early (ie, in CRI versus CR2)? 
What is the role of post-SCT therapy (chemotherapy; 
immunotherapy, ie, monoclonal antibodies and vaccination; 
and radiation therapy)? Which type of post-SCT therapy 
offers the best improvement in EFS and DFS? Results of 
ongoing studies are pending. 
With greater understanding of the complexity of molec- 
ular prognostic factors using gene microarray technology, 
how will risk-adapted therapy involving SCT be defined? 
Treatment-Related Research Questions 
What is the role of in vivo versus ex vivo purging using 
chemical or antibody selection? 
Will allogeneic SCTs with nonmyeloablative condition- 
ing regimens offer a graft-versus-lymphoma effect without 
the toxicity of a myeloablative allogeneic SCT? 
What is the role of gene therapy as a part of the condi- 
tioning regimen (eg, manipulation of both autologous and 
allogeneic cells, exogenous or knockout genes) for SCTs? 
What is the role of ex vivo expansion i  autologous and 
allogeneic SCTs? 
What is the optimal timing of infusion? 
Is there a role for dendritic ell therapy? 
What are the optimal combinations of chemotherapeu- 
tic and immunologic agents, radiation therapy, and gene 
therapy targets as conditioning regimens to produce the 
least oxicity and greatest therapeutic effect? 
XII. LIMITATIONS OF THIS EVIDENCE-BASED 
LITERMURE REVIEW 
There are limitations to any evidence-based review of 
the published medical literature. The criteria for this review 
included reliance on only published ata, specifically peer- 
reviewed articles published since 1980, and abstracts from 
the 3 most recent years of annual meetings where studies of 
SCT and/or NHL are presented. Unpublished ata, which 
were not included in this review, often represent "negative" 
findings and usually do not undergo peer review. We 
included studies presented in abstract form for the purpose 
of identifying "negative" clinical trials and preliminary 
analyses of "positive" clinical trials, with the understanding 
and acknowledgment that abstracts do not undergo rigorous 
peer review and do not contain the same level of study detail 
presented in published articles. 
Another limitation of this review is its reliance on pub- 
lished data rather than on individual patient data. The 
stated goal of the review was to present evidence for mak- 
ing recommendations regarding the role of SCT in the 
treatment of DLCL. Time and financial constraints made it 
impractical to obtain data on individual patients from the 
large number of clinical trials included in this review. 
Although it was not the objective of this review to perform 
an extensive meta-analysis of the data, such an analysis is 
warranted to further clarify the results of studies and 
address unanswered questions. 
Many studies were excluded from this analysis because 
they did not meet the stringent inclusion criteria for this 
review, namely the identification of histologic subtypes 
and the inclusion of at least 70% of patients having 
DLCL subtype. There were more than 170 publications 
(100+ abstracts and 70+ manuscripts) that described 
patients as having "aggressive lymphomas," "intermediate- 
and high-grade lymphomas," "high-grade lymphomas," 
and/or "malignant lymphomas" and did not specify the 
histologic subtypes. More than 80 publications (30+ 
abstracts and 50+ manuscripts) reported the histologic 
subtypes, but did not include a sufficient number of 
DLCL patients to enable the reviewers to reach a conclu- 
sion regarding the efficacy of transplantation i  this 
patient population. Most of the publications stated in the 
abstract or title that the authors tudied "aggressive" or 
"intermediate/high-grade" lymphomas, but there were 
significant differences in the proportion and distribution 
of the histologies studied. 
Most of the excluded studies addressed transplantation 
technologies (eg, autologous versus allogeneic donors, 
PBSCT versus BMT, purged versus unpurged BMT), rather 
than comparisons between SCT and standard chemo- 
therapy. These included several randomized trials and reg- 
istry reports comparing autologous and allogeneic BMT for 
lymphoma patients [86,87] and PBSCT versus BMT in 
NHL patients [88-93]. These and other studies could have 
provided much needed evidence in these areas but they 
could not be included because it was not stated whether the 
evidence was applicable to DLCL patients. 
It should also be noted that inclusion criteria were not 
based on the availability of patient IPI scores because most 
of the phase III trials were already accruing patients or had 
been analyzed prior to publication of the IPI project. It is 
acknowledged that significant differences in prognosis and 
outcomes by IPI have been identified, and applicability of 
results may be problematic if the IPI risk categories of 
patients are not stated. 
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XIII. FUTURE INITIATIVES 
This comprehensive, systematic review of the available 
evidence for the role of cytotoxic therapy with hemato- 
poietic stem cell transplantation in the therapy of diffuse EFS 
large cell non-Hodgkin's lymphoma is the first in a series of ESHAP 
sequential papers ponsored by the American Society for 
Blood and Marrow Transplantation. Each review will sum- FFP 
marize the evidence regarding the role of cytotoxic therapy FFS 
with SCT in the treatment of a specific disease using G-CSF 
defined methodology and grading criteria. GELA 
GM-CSF 
ECOG 
ECVBP 
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APPENDIX A. GLOSSARY OF ABBREVIATIONS 
IWF 
IWF F 
IWF G 
IWF H 
KPS 
LDH 
LY 
MACOP-B Aa-IPI Age-adjusted International Prognostic Index 
(See Appendix B for risk group definitions) 
ACVB Doxorubicin, cyclophosphamide, vindesine, 
bleomycin, and prednisolone 
ALCL Anaplastic large cell lymphoma 
ASBMT American Society for Blood and Marrow 
Transplantation 
BEAC Carmustine, toposide, cytarabine, and MegaCEOP 
cyclophosphamide 
BEAM Carmustine, toposide, cytarabine, and mel- 
phalan 
BM Bone marrow 
BMT Bone marrow transplant(ation) 
BNLI British National Lymphoma Investigation 
CBV Cyclophosphamide, carmustine, and etoposide 
CEEP Cyclophosphamide, epirubicin, vindesine, and 
prednisone 
CEOP Cyclophosphamide, epirubicin, vincristine, 
and prednisone 
CHOP Cyclophosphamide, oxorubicin, vincristine, 
and prednisone 
CNS Central nervous ystem 
CR Complete response/remission 
CRu CR with scan abnormalities ofunknown sig- 
nificance 
CT Cyclophosphamide and TBI 
DFS Disease-free survival 
DHAP Dexamethasone, cisplatin, and cytarabine 
DLCL Diffuse large cell B-cell non-Hodgkin's lym- 
phoma 
MAD 
MBIDCOS 
MINE 
NCI 
NHL 
NS 
OS 
PBSC 
PBSCT 
PFS 
PR 
ProMACE- 
MOPP 
PS 
QALY 
REAL 
RFS 
RR 
SCT 
SWOG 
Eastern Cooperative Oncology Group 
Epirubicin, cyclophosphamide, vindesine, 
bleomycin, and prednisone 
Event-free survival 
Etoposide, methylprednisolone, high-dose 
cytarabine, and cisplatin 
Freedom from progression 
Failure-free survival 
Granulocyte colony-stimulating factor 
Groupe d'Etude des Lymphomes de l'Adulte 
Granulocyte macrophage-colony stimulating 
factor 
Graft-versus-host disease 
Hodgkin's disease 
High-dose sequential (therapy) 
Ifosfamide, carboplatin, etoposide 
Idarubicin, cisplatin, cytarabine, and methyl- 
prednisone 
Induction failure 
Involved field radiotherapy 
PR to induction therapy 
International Prognostic Index (See Appendix 
B for risk group definitions) 
International Working Formulation 
Diffuse mixed small and large cell NHL 
Diffuse large cell NHL 
Diffuse large cell immunoblastic NHL 
Karnofsky Performance Status 
Lactate dehydrogenase 
Life years 
Methotrexate, doxorubicin, cyclophos- 
phamide, vincristine, prednisone, and 
bleomycin 
Mitoxantrone, cytarabine, and dexamethasone 
Methotrexate, l ucovorin calcium, idarubicin, 
vincristine, bleomycin, cyclophosphamide, 
and methylprednisolone 
Cyclophosphamide (1200 mg/m2), epirubicin 
2 2 (110 mg/m ), vincristine (1.4 mg/m ), and 
prednisone (40 mg/m 2) 
Mesna, ifosfamide, mitoxantrone, etoposide 
National Cancer Institute (U.S.) 
Non-Hodgkin's lymphoma 
Not statistically significant 
Overall survival 
Peripheral blood stem cell(s) 
Peripheral blood stem cell transplant(ation) 
Progression-free survival 
Partial response/remission 
Prednisone, methotrexate, doxorubicin, 
cyclophosphamide, etoposide, mechlor- 
ethamine, vincristine, and procarbazine 
Performance status 
Quality adjusted life years 
Revised European-American Classification of 
Lymphoid Neoplasms 
Relapse-free survival 
Relative risk 
Hematopoietic stem cell transplant(ation) 
Southwest Oncology Group 
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TBI 
VACOP-B 
VAPEC-B 
VCT 
WHO 
Total body irradiation 
Etoposide, doxorubicin, cyclophosphamide, 
vincristine, prednisone, and bleomycin 
Vincristine, doxorubicin, prednisolone, topo- 
side, cyclophosphamide, and bleomycin 
Etoposide, cyclophosphamide, and TBI 
World Health Organization 
APPENDIX  B. DEF IN IT ION OF INTERNATIONAL 
PROGNOSTIC  INDEX MODELS [12]  
Inte~Tational Prognostic Index (IPI) Model for All Patients 
Risk factors: 
Age >60 
LDH > normal 
ECOG PS > 7. 
Ann Arbor stage Ill-IV 
> I extranodal site 
Risk Group: Number of Risk Factors 
Low 0- I 
Low-intermediate 2 
High-intermediate 3 
High 4-5 
Age-Adjusted International Prognostic Index (AalPI) Model for Patients 
<60 Years Old 
Risk Factors* 
LDH > normal 
ECOG PS -> 2 
Ann Arbor stage Ill-IV 
Risk Group Number of Risk Factors 
Low 0 
Low-intermediate I 
High-intermediate 2 
High 3 
*>1 extranodal site of disease was not a significant independent pre- 
dictor of survival in patients -<60 years old. 
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